SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third ShotArticle Published on 2022-02-212022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] Antibody titer BNT162b2 vaccine clinically COVID-19 dose eight fingolimod homologous humoral immune response IgG antibody IgG response IgG titer immunization individual mRNA mRNA vaccine mRNA-1273 mRNA-based vaccine Multiple multiple sclerosis overcome Protective quantified receptor response S1PR-modulator SARS-CoV-2 SARS-CoV-2 vaccine sclerosis Serum level the receptor-binding domain treated vaccination [DOI] 10.3390/vaccines10020341 PMC 바로가기 [Article Type] Article
Higher SARS-CoV-2 Spike Binding Antibody Levels and Neutralization Capacity 6 Months after Heterologous Vaccination with AZD1222 and BNT162b2Article Published on 2022-02-172022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anti-spike IgG levels AZD1222 BNT162b2 breakthrough infections Capacity Cellular immune response clinically evaluated comparable COVID-19 Delta delta variant Efficacy group Health care worker heterologous prime-boost Heterologous prime-boost vaccination highest homologous humoral humoral and cellular immune response IFNγ Level magnitude Month neutralizing capacity offered peptide peptides question Receptor binding domain recruited regimen resulting SARS-CoV-2 SARS-CoV-2 vaccine secretion significantly significantly higher spike symptomatic disease the vaccine vaccination Vaccinations Vaccine variant of concern variants of concern viral neutralization wild type Wuhan-Hu-1 [DOI] 10.3390/vaccines10020322 PMC 바로가기 [Article Type] Article
Capturing a Crucial ‘Disorder-to-Order Transition’ at the Heart of the Coronavirus Molecular Pathology—Triggered by Highly Persistent, Interchangeable Salt-BridgesArticle Published on 2022-02-162022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] anionic appear arginine baseline being binding catalytic cationic characteristic cleavage site coronavirus COVID-19 disorder disorder-to-order transition enthalpy entropy compensation entropy arrest events Evolution feature FLCS flexible furin cleavage Genome heart homologous Host increase in Interaction interactions Lineage Molecular pathology motif multiplicity offer persistent polybasic Protein proteolytic proteolytic cleavage residue respiratory viral diseases respiratory viruses S1/S2 junction salt-bridge salt-bridge dynamics SARS-CoV SARS-CoV-2 spike Spike–Furin interaction the SARS-CoV-2 Transmissibility [DOI] 10.3390/vaccines10020301 PMC 바로가기 [Article Type] Article
Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany독일 성인 인구의 체액성 SARS-CoV-2 백신 반응의 비교 규모 및 지속성Multicenter Study Published on 2022-02-162022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 binding analyzed antibodies antibody antibody persistence Antibody Response Antibody titre antibody titres booster Comparative concerning dose Efficacy explain focus Germany healthcare Healthcare workers heterologous prime-boost homologous immune protection immune response immune responses immunocompromised individual immunocompromised individuals increases in infected individual information longitudinal study mRNA vaccination mRNA vaccines mRNA-based Neutralizing peaked Population population-based study produced proportion protective immunity question RBD recent recipient recipients reduced response robust SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 infections second vaccination significantly higher specific antibodies subpopulation subpopulations titre triggered vaccination Vaccine vaccine-induced immune response vaccine-induced immune responses variants variants of concern vector-based vaccines while wild-type [DOI] 10.3389/fimmu.2022.828053 PMC 바로가기 [Article Type] Multicenter Study
Identification of Crucial Genes and Key Functions in Type 2 Diabetic Hearts by Bioinformatic Analysis생물정보학적 분석을 통한 제2형 당뇨병 심장의 핵심 유전자 및 주요 기능 식별Endocrinology Published on 2022-02-152022-09-11 Journal: Frontiers in Endocrinology [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, [키워드] Acute cardiac injury Analysis Autopsy Bioinformatic bioinformatic analysis bioinformatics calpain calpain small subunit 1 (capn4) CAPNS1 cardiac cardiac injury conducted COVID-19 cytoplasmic Cytoscape dataset datasets dead DEGs DESeq2 develop diabete diabetes differentially expressed gene Differentially expressed genes down-regulated endopeptidase event events exhibited expression profile expression profiles function functions Gene ontology healthy heart hearts highlight homologous Hospitalized Human hydrolysis hydrolyzed identification identify Infection Interaction Kyoto leads less mechanism membrane mice Mitochondria molecular Mybpc3 Myocardium NCBI-Gene NCBI-GEO nuclear translocation overlapping pathogenic pathway patients with SARS-CoV-2 performed PPI PPI network prognostic progression protein-protein interaction reduced RNA-sequencing SARS-COV-2 infection self-protective role Serine Signaling significantly significantly increased small subunit specimen substrate syndrome T2D therapy Tnni3 Transcription transcriptional change transcriptional level Transcriptional upregulation transcriptomics Type type 2 diabetes unique up-regulated with COVID-19 [DOI] 10.3389/fendo.2022.801260 PMC 바로가기 [Article Type] Endocrinology
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipientsAd26.COV2.S 백신 수용자에서 동종 대 이종 부스트의 차등 면역원성Article Published on 2022-02-112022-09-11 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus Adenovirus Vector Antiviral antiviral immunity BNT162b2 boost breadth cellular immune responses cellular immunity ChAdOx1 ChAdOx1 nCoV-19 college coronavirus disease Coronavirus disease 2019 COV2.S COVID-19 dose ENhance feature Heterologous heterologous immunity heterologous vaccine homologous homologous or heterologous humoral immune responses immunological immunological parameter individual individuals knowledge lack Medical Research Council Ministry of Health mRNA of BNT162b2 offered protection pump quantity recipient second dose Singapore single dose small sample size SMD specific antibodies spike-specific antibodies Spike-specific antibody Support supported T cell T cells Trustee utilization vaccination Vaccine Vaccines [DOI] 10.1016/j.medj.2021.12.004 PMC 바로가기 [Article Type] Article
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종Clinical Trial Published on 2022-02-052022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial
Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies불활성화 백신의 동종 또는 이종 부스터는 중화 항체로부터 SARS-CoV-2 오미크론 변이체 탈출을 감소시킵니다.Coronaviruses Published on 2022-02-042022-09-10 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accumulated addition antibodies Antibody titer B.1.1.529 BBIBP-CorV booster booster vaccination convalescent dose eight epitope Epitopes Heterologous homologous homologous or heterologous identified variant inactivated Inactivated vaccine individual less mAb mAbs monoclonal antibodies monoclonal antibody neutralization neutralization titer neutralization titers Neutralizing neutralizing antibody Neutralizing antibody titer NTD omicron Omicron variant protein subunit vaccine pseudovirus raising RBD reduce reduction SARS-CoV-2 SARS-CoV-2 variants sera Seven significantly increased spike mutations Subunit vaccine tested the vaccine therapeutic therapeutic antibodies transmission of SARS-CoV-2 urgency Vaccine variant Viral viral variant VOCs ZF2001 [DOI] 10.1080/22221751.2022.2030200 PMC 바로가기 [Article Type] Coronaviruses
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cellsSARS-CoV-2에 대한 고친화성 중화 항체는 T 여포 보조 세포 없이 만들 수 있습니다.Article Published on 2022-02-042022-09-11 Journal: Science Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] (Beta absence Alternative pathway antibody antibody production Antiviral B cell B cell response B cell responses B.1.351 Cell cell interaction cell interactions cells complement damaged driver effective epitope epitope mapping Epitopes Evidence evidence of follicular Germinal center high affinity homologous Immunoglobulin immunoglobulin class immunoglobulin class switching Infection Inflammation Influenza influenza A influenza A virus influenza A virus infection Neutralizing neutralizing antibody occur operative pathway Patient patients Protective reactive receptor reduced responses SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Sequencing severe COVID-19 Support switching T cell These data variant Viral viral infection virus infection [DOI] 10.1126/sciimmunol.abl5652 PMC 바로가기 [Article Type] Article
Omicron’s message on vaccines: Boosting begets breadth백신에 대한 오미크론의 메시지: 부스팅은 폭을 낳습니다Comment Published on 2022-02-032022-09-11 Journal: Cell [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Adaptability antibodies antibody booster breadth evade highlight homologous immune immune memory Immunity induce neutralization Neutralizing antibodies omicron recalled regimen SARS-CoV-2 SARS-CoV-2 variants Vaccine [DOI] 10.1016/j.cell.2022.01.006 PMC 바로가기 [Article Type] Comment